Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;43(2):763-766.
doi: 10.1007/s10072-021-05761-7. Epub 2021 Nov 19.

ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination

Laura Mumoli  1 , Virginia Vescio  2 , Domenico Pirritano  3 , Emilio Russo  4 , Domenico Bosco  3
Affiliations

ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination

Laura Mumoli et al. Neurol Sci. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
MRI of spinal cord at onset on short tau inversion recovery (STIR) images showed large confluent lesions extending over multiple segments until conus (white arrows) (A) without cord swelling and without enhancement after gadolinium on T1-weighted image with gadolinium (B). Three months later on STIR images disappeared completely hyperintense steak (C), none enhancement after gadolinium on T1 weighted image (D)
Fig. 2
Fig. 2
Brain axial fluid-attenuated inversion recovery weighted (FLAIR) images at onset showed bilateral diffuse multifocal poorly marginated, large asymmetric lesions of white matter, basal ganglia and cortical gray matter with asymmetric involvement of thalami (A, B see white arrows). A tumefactive lesion on left frontal lobe was detected too (C). Brain axial T1-weighted image did not show enhancement after gadolinium (from D to F). Three months later, axial FLAIR images showed a complete resolution of the lesions (from G to L) and no enhancement after gadolinium on T1-weighted image was detected too (M, N)
See this image and copyright information in PMC

Comment in

References

    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of pediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatric. 2014;86:265–272. doi: 10.1136/jnnp-2014-308346. - DOI - PubMed
    1. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4. - DOI - PMC - PubMed
    1. Cao L, Ren L (2021) Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurol Bel. 10.1007/s13760-021-01608-2 - PMC - PubMed
    1. Vogrig A, Janes F. Gian Luigi Gigli, Francesco Curcio, Ilaria Del Negro, Serena D'Agostini, Martina Fabris, Mariarosaria Valente Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg. 2021;208:106839. doi: 10.1016/j.clineuro.2021.106839. - DOI - PMC - PubMed